Diversity Compound Libraries for early drug discovery
MCE provides 90,000+ bioactive molecules and 200+ compound libraries.
Drug discovery is a time and resource consuming process, which includes initial target identification and validation, biological assay development, hit identification and validation, hit to lead optimization, lead to candidate optimization, and preclinical trials to select a candidate molecule for clinical development [ref. 1]. In the step of hit identification, screening techniques, such as high throughput screening (HTS) and virtual screening (VS), are employed to identify hit molecules that are able to interact with the fully validated target or have high activity in cell-based assays (Figure 1) [ref. 1]. The screening attrition rate in the current drug discovery protocols suggests that one marketable drug emerges from approximately one million screened compounds. A high-quality diversity compound library is the key to a successful hit identification campaign, it helps to save time and reduce cost by maximizing the number of initial hits while reducing the amount of false positives [ref. 2].
Because of the complex nature of biological targets, screening a library with high level of functional and structural diversities increases the chance of identifying hit compounds with the desired properties [ref. 3]. Recent advances in combinatorial chemistry and diversity-oriented synthesis (DOS) allow the construction of small-molecule libraries containing structurally diverse scaffolds, and various bioactive compounds against undruggable targets were identified from unbiased phenotypic screens using these libraries [ref. 4]. MedChemExpress offers a large collection of commercially available compound libraries with high structural and functional diversities. Our customers have used these libraries and discovered many hit compounds in their research. For example, Charbord., et al. [ref. 5] identified a SIK inhibitor through in vivo screen that induces β cell proliferation. Zhang., et al. [ref. 6] found SARS-CoV-2 main and papain-like protease inhibitors through high-throughput screening. To meet the increasing demands for diversity compound libraries, MedChemExpress recently launched two unique scaffold collections (Table 1) with high skeletal diversity, high functional group diversity, and broad chemical space coverage.